Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: Analysis of the FDA adverse event report system database

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 27, Issue 12, 2017, Pages 1108-1113

  Perlman, A ^a,b   Heyman, S N ^a   Matok, I ^b   Stokar, J ^a   Muszkat, M ^a   Szalat, A ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Adverse effects; Diabetes; Renal failure; SGLT2 inhibitors

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

ACUTE KIDNEY FAILURE; ADVERSE EVENT; ARTICLE; DISABILITY; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; HOSPITALIZATION; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CHI SQUARE DISTRIBUTION; FACTUAL DATABASE; METABOLISM; ODDS RATIO; PATIENT SAFETY; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; TIME FACTOR; UNITED STATES;

ACUTE KIDNEY INJURY; ADVERSE DRUG REACTION REPORTING SYSTEMS; CHI-SQUARE DISTRIBUTION; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; LOGISTIC MODELS; ODDS RATIO; PATIENT SAFETY; PHARMACOVIGILANCE; RISK ASSESSMENT; RISK FACTORS; SODIUM-GLUCOSE TRANSPORTER 2; TIME FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 85034996868     PISSN: 09394753     EISSN: 15903729     Source Type: Journal    
DOI: 10.1016/j.numecd.2017.10.011     Document Type: Article

References (30)

1. Zaccardi, F., Webb, D.R., Htike, Z.Z., Youssef, D., Khunti, K., Davies, M.J., Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes, Obes Metab 18 (2016), 783–794.
2. Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
3. Wanner, C., Inzucchi, S.E., Lachin, J.M., Fitchett, D., von Eynatten, M., Mattheus, M., et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375 (2016), 323–334.
4. Neal, B., Perkovic, V., Mahaffey, K.W., de Zeeuw, D., Fulcher, G., Erondu, N., et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377 (2017), 644–657.
5. Heyman, S.N., Khamaisi, M., Rosen, S., Rosenberger, C., Abassi, Z., Potential hypoxic renal injury in patients with diabetes on SGLT2 inhibitors: caution regarding concomitant use of NSAIDs and iodinated contrast media. Diabetes Care 40 (2017), e40–e41.
6. O'Neill, J., Fasching, A., Pihl, L., Patinha, D., Franzén, S., Palm, F., Acute SGLT inhibition normalizes O 2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats. Am J Physiol - Ren Physiol 309 (2015), F227–F234.
7. Vasilakou, D., Karagiannis, T., Athanasiadou, E., Mainou, M., Liakos, A., Bekiari, E., et al. Sodium–Glucose cotransporter 2 inhibitors for type 2 diabetes. Ann Intern Med, 159, 2013, 262.
8. Storgaard, H., Gluud, L.L., Bennett, C., Grøndahl, M.F., Christensen, M.B., Knop, F.K., et al. Benefits and harms of sodium-glucose Co-Transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis. PLoS One, 11, 2016, e0166125.
9. Tang, H., Li, D., Zhang, J., Li, Y., Wang, T., Zhai, S., et al. Sodium-glucose cotransporter 2 inhibitors and risk of adverse renal outcomes among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials. Diabetes Obes Metab, 2017.
10. http://bioportal.bioontology.org/ontologies/MEDDRA?p=classes&conceptid=20000003.
11. Evans, S.J.W., Waller, P.C., Davis, S., Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 10 (2001), 483–486.
12. Harpaz, R., DuMouchel, W., LePendu, P., Bauer-Mehren, A., Ryan, P., Shah, N.H., Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system. Clin Pharmacol Ther 93 (2013), 539–546.
13. Raschi, E., Poluzzi, E., Koci, A., Salvo, F., Pariente, A., Biselli, M., et al. Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system. Br J Clin Pharmacol, 2015.
14. Sakaeda, T., Tamon, A., Kadoyama, K., Okuno, Y., Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci 10 (2013), 796–803.
15. Rothman, K.J., Lanes, S., Sacks, S.T., The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf 13 (2004), 519–523.
16. Weber, J., Epidemiology of adverse reactions to nonsteroidal antiinflammatory drugs. Adv Inflamm Res, 61, 1984.
17. Hartnell, N.R., Wilson, J.P., Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration. Pharmacotherapy 24 (2004), 743–749.
18. Poluzzi, E., Raschi, E., Piccinni, C.D.F., Data mining techniques in pharmacovigilance: analysis of the publicly accessible FDA adverse event reporting system (AERS). Karahoca, A., (eds.) Data Min Appl Eng Med, InTech, 2012, 265–302.
19. Hoffman, K.B., Demakas, A.R., Dimbil, M., Tatonetti, N.P., Erdman, C.B., Stimulated reporting: the impact of US food and drug administration-issued alerts on the adverse event reporting system (FAERS). Drug Saf 37 (2014), 971–980.
20. Hoffman, K.B., Dimbil, M., Erdman, C.B., Tatonetti, N.P., Overstreet, B.M., The weber effect and the United States food and drug Administration's adverse event reporting system (FAERS): analysis of sixty-two drugs approved from 2006 to 2010. Drug Saf 37 (2014), 283–294.
21. Lambers Heerspink, H.J., de Zeeuw, D., Wie, L., Leslie, B., List, J., Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 15 (2013), 853–862.
22. Heyman, S.N., Khamaisi, M., Rosenberger, C., Szalat, A., Abassi, Z., Increased hematocrit during sodium-glucose Cotransporter-2 inhibitor therapy. J Clin Med Res 9 (2017), 176–177.
23. Supplement to, Zinman, B., Wanner, C., Lachin, J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128, 10.1056/NEJMoa1504720 2015.
24. Downing, N.S., Shah, N.D., Aminawung, J.A., Pease, A.M., Zeitoun, J.-D., Krumholz, H.M., et al. Postmarket safety events among novel therapeutics approved by the US food and drug administration between 2001 and 2010. JAMA, 2017, 1854, 317.
25. Protocol for, Neal, B., Perkovic, V., Mahaffey, K.W., et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 376 (2017), 644–657, 10.1056/NEJMoa1611925 n.d.
26. Mandal, A.K., Markert, R.J., Saklayen, M.G., Mankus, R.A., Yokokawa, K., Diuretics potentiate angiotensin converting enzyme inhibitor-induced acute renal failure. Clin Nephrol 42 (1994), 170–174.
27. Bakris, G.L., Sarafidis, P.A., Weir, M.R., Dahlöf, B., Pitt, B., Jamerson, K., et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet (London, Engl 375 (2010), 1173–1181.
28. Knight, E.L., Glynn, R.J., McIntyre, K.M., Mogun, H., Avorn, J., Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD). Am Heart J 138 (1999), 849–855.
29. Scheen, A.J., Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin Pharmacokinet 53 (2014), 213–225.
30. Baartscheer, A., Schumacher, C.A., Wüst, R.C.I., Fiolet, J.W.T., Stienen, G.J.M., Coronel, R., et al. Empagliflozin decreases myocardial cytoplasmic Na(+) through inhibition of the cardiac Na(+)/H(+) exchanger in rats and rabbits. Diabetologia 60 (2017), 568–573.